Pernix Therapeutics, Inc.
P.O. Box 40
Gonzales
Louisiana
70707-0040
United States
Tel: 800-793-2145
Website: http://pernixtx.com/
159 articles with Pernix Therapeutics, Inc.
-
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
-
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
-
TEDOR Pharma Announces Recapitalization and New Management
5/16/2018
TEDOR Pharma, Inc., a full-service, end-to-end, contract development and manufacturing company (CDMO) founded in 2001, today announced the closing of a recapitalization and reorganization of its business, funded by investments from DORA Ventures, Inc.
-
Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals
4/24/2018
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash. -
Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion
2/7/2018
The company announced the appointment of Director John R. Leone as its Lead Independent Director.
-
Pernix Announces Patent Litigation Settlement Agreement With Actavis Concerning Zohydro ER
1/29/2018
The litigation has been pending in the U.S. District Court for the District of Delaware and resulted from Actavis’s submission of an ANDA to the FDA seeking approval to market a generic version of Zohydro ER.
-
Pfizer Quits Neuroscience R&D
1/8/2018
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut. -
The company will undergo a reorganization that includes the termination of a number of sales representatives.
-
Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors
11/16/2017
The Company’s Board remains at five members, four of whom are independent, as incumbent directors.
-
Pernix Therapeutics Reports Third Quarter 2017 Financial Results
11/8/2017
Third quarter 2017 net revenues were $40.5 million, an 18% increase sequentially from $34.3 million recorded in the second quarter of 2017.
-
Pernix Therapeutics Announces Sale of Non-Core Product
11/7/2017
Cedax was discontinued by Pernix in 2016 and the Company has not generated any sales from this product in 2017.
-
Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7
10/26/2017
Management will host a conference call to discuss the results.
-
Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
10/18/2017
Graham Miao, Ph.D., President and Chief CFO, will leave the Company at the end of the year in order to pursue other opportunities.
-
Pernix Reports Second Quarter 2017 Financial Results And Provides Business Update
7/28/2017
-
Pernix Added To Russell Microcap Index
6/29/2017
-
Pernix Reports First Quarter 2017 Financial Results And Provides Business Update
5/16/2017
-
Pernix To Report First Quarter 2017 Financial Results On Monday, May 15
5/9/2017
-
Pernix Provides Update On Availability Of Zohydro ER With Beadtek 20mg Strength
5/1/2017
-
Pernix Announces Fourth Quarter And Full Year 2016 Financial Results
3/29/2017
-
Pernix To Report Fourth Quarter And Year-End 2016 Financial Results On Tuesday, March 28
3/16/2017